Stay updated with breaking news from Nasdaq Abos. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS – Get Free Report) saw a significant increase in short interest in June. As of June 30th, there was short interest totalling 191,400 shares, an increase of 26.8% from the June 15th total of 151,000 shares. Currently, 0.7% of the company’s stock are short sold. Based on an average daily trading […]
Topline results from INTERCEPT-AD trial met primary and secondary objectives, demonstrating proof-of-mechanism for ACU193, the first clinical-stage amyloid...
Acumen Pharmaceuticals (NASDAQ:ABOS – Get Rating) and Repligen (NASDAQ:RGEN – Get Rating) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, risk, profitability, valuation, earnings and dividends. Risk and Volatility Acumen Pharmaceuticals has a beta of -1.55, suggesting […]
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS – Get Rating) saw a large decline in short interest in the month of May. As of May 15th, there was short interest totalling 159,800 shares, a decline of 26.3% from the April 30th total of 216,800 shares. Currently, 0.6% of the shares of the company are short sold. Based on […]
Cantor Fitzgerald began coverage on shares of Acumen Pharmaceuticals (NASDAQ:ABOS – Get Rating) in a report issued on Thursday, The Fly reports. The brokerage issued an overweight rating and a $13.00 price objective on the stock. Other research analysts also recently issued research reports about the company. Credit Suisse Group lowered their target price on […]